{
    "id": 25775,
    "fullName": "FGF2 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "FGF2 positive indicates the presence of the FGF2 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2247,
        "geneSymbol": "FGF2",
        "terms": [
            "FGF2",
            "BFGF",
            "FGF-2",
            "FGFB",
            "HBGF-2"
        ]
    },
    "variant": "positive",
    "createDate": "12/01/2016",
    "updateDate": "12/01/2016",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20157,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II (FINESSE) trial, Fgf2 expression was not correlated with progression-free survival in patients with metastatic hormone receptor-positive, Erbb2 (Her2)-negative breast cancer treated with Lucitanib (E-3810) (PMID: 31619444; NCT02053636).",
            "molecularProfile": {
                "id": 26858,
                "profileName": "FGF2 positive"
            },
            "therapy": {
                "id": 1029,
                "therapyName": "Lucitanib",
                "synonyms": null
            },
            "indication": {
                "id": 60080,
                "name": "Her2-receptor negative breast cancer",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 17719,
                    "pubMedId": 31619444,
                    "title": "Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31619444"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9500,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FGFR1 demonstrated resistance to treatment with Quizartinib (AC220) in the presence of FGF2 ligand in culture (PMID: 27671675).",
            "molecularProfile": {
                "id": 26859,
                "profileName": "FGF2 pos FGFR1 pos FLT3 exon 14 ins"
            },
            "therapy": {
                "id": 882,
                "therapyName": "Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 7227,
                    "pubMedId": 27671675,
                    "title": "FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27671675"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9502,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Quizartinib (AC220) and PD173074 resulted in a synergistic effect in the presence of FGF2 ligand in acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FGFR1 in culture (PMID: 27671675).",
            "molecularProfile": {
                "id": 26859,
                "profileName": "FGF2 pos FGFR1 pos FLT3 exon 14 ins"
            },
            "therapy": {
                "id": 5041,
                "therapyName": "PD173074 + Quizartinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7227,
                    "pubMedId": 27671675,
                    "title": "FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27671675"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9499,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FGFR1 demonstrated sensitivity to treatment with PD173074 in the presence of FGF2 ligand in culture, resulting in decreased cell viability (PMID: 27671675).",
            "molecularProfile": {
                "id": 26859,
                "profileName": "FGF2 pos FGFR1 pos FLT3 exon 14 ins"
            },
            "therapy": {
                "id": 2948,
                "therapyName": "PD173074",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7227,
                    "pubMedId": 27671675,
                    "title": "FGF2 from Marrow Microenvironment Promotes Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27671675"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 26858,
            "profileName": "FGF2 positive",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26859,
            "profileName": "FGF2 pos FGFR1 pos FLT3 exon 14 ins",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}